Vaxxinova Acquires Newport Labs From Boehringger Ingelheim

87

Vaxxinova announced today that it has purchased Newport Laboratories, a company that manufactures custom-made vaccines for swine and cattle, from Boehringer Ingelheim.

About 100 people work at Newport Laboratories in Worthington, Minnesota. They help veterinarians and livestock producers address animal health issues through diagnostic testing and production of autogenous, or custom-made, vaccines.

Vaxxinova CEO Victor van Solinge said his team is committed to a smooth transition to support of Newport Laboratories customers. “We are proud to add Newport Laboratories to the group of Vaxxinova companies. It is a perfect fit with our strategy to grow and improve our products and services for livestock producers and veterinarians,” he said. “Newport and Vaxxinova US (previously known as Epitopix) have complementary portfolios and similar company cultures. We are confident that our customers will benefit from this new combination.” Terms of the deal were not disclosed.

“Newport Laboratories has a proud history of helping protect cattle and swine from disease through custom-made vaccines, and this transaction lets Newport Laboratories continue that legacy,” said Steve Boren, Vice President of the Livestock business at Boehringer Ingelheim Animal Health USA Inc. “I am pleased that Vaxxinova is purchasing Newport Laboratories and believe that Vaxxinova can realize the full potential of the custom-made vaccine business. “Additionally, the divesture allows Boehringer Ingelheim to continue its focus on helping producers and veterinarians with our full array of well-established commercial brands based on our deep expertise in cattle and swine.”

Jim Sandstrom, DVM, managing director of Vaxxinova US said that Vaxxinova hopes to ensure a fast, seamless transfer. “Our aim is to have zero disruptions in product supply and service, and to begin delivering synergies to customers as quickly as possible” he said. “In addition, Vaxxinova US customers will also benefit from Newport Laboratories’ state of art diagnostic center, which provides excellent diagnostic services to the industry.”

About Vaxxinova International BV

Vaxxinova International BV is a global animal health player specialized in disease and performance management of production animals. The company operates in more than 50 countries and has its headquarters in Nijmegen, The Netherlands. Vaxxinova has R&D, production and diagnostic facilities in Brazil, Chile, Germany, Italy, Japan, Jordan, the Netherlands, Norway and USA. Vaxxinova is 100% owned by the EW Group, with headquarters in Visbek, Germany.
Vaxxinova announced today that it has purchased Newport Laboratories, a company that manufactures custom-made vaccines for swine and cattle, from Boehringer Ingelheim.

About 100 people work at Newport Laboratories in Worthington, Minnesota. They help veterinarians and livestock producers address animal health issues through diagnostic testing and production of autogenous, or custom-made, vaccines.

Vaxxinova CEO Victor van Solinge said his team is committed to a smooth transition to support of Newport Laboratories customers. “We are proud to add Newport Laboratories to the group of Vaxxinova companies. It is a perfect fit with our strategy to grow and improve our products and services for livestock producers and veterinarians,” he said. “Newport and Vaxxinova US (previously known as Epitopix) have complementary portfolios and similar company cultures. We are confident that our customers will benefit from this new combination.” Terms of the deal were not disclosed.

“Newport Laboratories has a proud history of helping protect cattle and swine from disease through custom-made vaccines, and this transaction lets Newport Laboratories continue that legacy,” said Steve Boren, Vice President of the Livestock business at Boehringer Ingelheim Animal Health USA Inc. “I am pleased that Vaxxinova is purchasing Newport Laboratories and believe that Vaxxinova can realize the full potential of the custom-made vaccine business. “Additionally, the divesture allows Boehringer Ingelheim to continue its focus on helping producers and veterinarians with our full array of well-established commercial brands based on our deep expertise in cattle and swine.”

Jim Sandstrom, DVM, managing director of Vaxxinova US said that Vaxxinova hopes to ensure a fast, seamless transfer. “Our aim is to have zero disruptions in product supply and service, and to begin delivering synergies to customers as quickly as possible” he said. “In addition, Vaxxinova US customers will also benefit from Newport Laboratories’ state of art diagnostic center, which provides excellent diagnostic services to the industry.”

About Vaxxinova International BV

Vaxxinova International BV is a global animal health player specialized in disease and performance management of production animals. The company operates in more than 50 countries and has its headquarters in Nijmegen, The Netherlands. Vaxxinova has R&D, production and diagnostic facilities in Brazil, Chile, Germany, Italy, Japan, Jordan, the Netherlands, Norway and USA. Vaxxinova is 100% owned by the EW Group, with headquarters in Visbek, Germany.